Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.
Immune thrombocytopenia (ITP) is a severe bleeding disorder. Approximately 2/3 of patients achieve remission from first-line therapies. However, the underlying mechanism of corticosteroid-resistant or relapsed ITP is not well understood; thus, treatment remains a great challenge. Atorvastatin was shown to enhance bone marrow endothelial cell function and N-acetylcysteine (NAC) was shown to inhibit PLT binding to endothelial cell. A multicentre prospective study was performed in non-splenectomized ITP patients who were either resistant to a standard dose of corticosteroids or had relapsed. Patients were randomized to atorvastatin, acetylcysteine plus danazol with danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study, in order to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Atorvastatin was used in combination with acetylcysteine and danazol.
Acetylcysteine was used in combination with atorvastatin and danazol.
Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
the sustained platelet response at the 6-month follow-up
The number of participants (responders) with platelet count \>=30x10\^9/L and at least a 2-fold increase in the baseline count (PR) or a platelet count \>=100x10\^9/L (CR) and the absence of bleeding, without rescue medication at 6-month follow-up.
Time frame: From the start of study treatment (Day 1) up to the end of Month 6
overall response
The number of participants with platelet count \>=30×10\^9/L at least once and at least a doubling of the baseline platelet count without the administration of any other platelet increasing therapy.
Time frame: From the start of study treatment (Day 1) up to the end of Month 6
time to response
Time to response was defined as the time from starting treatment to the time to achieve the response.
Time frame: From the start of study treatment (Day 1) up to the end of Year 2
duration of response
Duration of response was measured from the achievement of response to the loss of response.
Time frame: From the start of study treatment (Day 1) up to the end of Year 2
incidence of treatment-emergent adverse events
All patients were assessed for treatment-emergent adverse events every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: From the start of study treatment (Day 1) up to the end of Year 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.